By Marie Rosenthal
Teva Pharmaceutical Industries Ltd. launched a generic version of the branded antiretroviral therapy (ART), Reyataz (atazanavir, Bristol-Myers Squibb), in the United States.
Atazanavir sulfate capsules are a protease inhibitor (PI) indicated for use in combination with other ART for the treatment of HIV-1 infection in patients aged 6 years and older weighing at least 15 kg. Atazanavir sulfate is not recommended for use in children younger than 3 months of age due to the risk